Nmda nr2b antagonists for the treatment of depression
CA 2357929 A1 · Owner: Saltarelli, Mario David · Inventors: Saltarelli, Mario David; Chenard, Bertrand Leo; Menniti, Frank Samuel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides new methods for treating certain disorders resulting from, neurodegeneration and for treating depression which comprise administration of NR2B, subunit selective NMDA antagonists. The disorders that can be treating by the invention, include hearing loss, vision loss neurodegeneration caused by epileptic seizures, neurotoxin, poisoning, Restless Leg Syndrome multi-system atrophy, non-vascular headache and, depression.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 28, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.